속보 • Jul 08
ProLogium Advances De-SPAC Merger Process With TDAC After SEC F-4 Filing Translational Development Acquisition announced that ProLogium has filed its initial Form F-4 registration statement with the SEC, a key step in progressing their planned de-SPAC merger.
The F-4 filing provides the SEC and investors with more detailed information on ProLogium’s history and the proposed business combination, moving the transaction further along the regulatory process.
TDAC units last traded at $11.60, with the stock down 27.2% over the past 30 days, indicating recent share price pressure despite the merger process advancing.
This filing marks a formal point where investors can expect more comprehensive disclosures about ProLogium and the merger terms. These disclosures can help in assessing how the combined company might look and what deal risks remain, including regulatory review, shareholder approval, and any potential changes to the transaction structure. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorates as stock falls 28% After last week's 28% share price decline to US$11.50, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 40x in the Capital Markets industry in the US. Total returns to shareholders of 11% over the past year. 공시 • May 29
Prologium Holdings Inc. agreed to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction. Prologium Holdings Inc. ntered into a definitive agreement to acquire Translational Development Acquisition Corp. (NasdaqGM:TDAC.U) from TDAC Partners LLC for approximately $3.8 billion in a reverse merger transaction on May 27, 2026. The transaction values Prologium at approximately $3.8 billion on a pre-money, net cash-free basis. Upon closing, ProLogium will own 92% of the combined company with SPAC & PIPE Investors owning 7%, and SPAC Sponsor owning 1%. Upon completion, the combined company is expected to be named ProLogium Technology and to be listed on Nasdaq under the ticker symbol "PRLG".
As part of the transaction, the post-closing board shall consist of nine directors whom one individual is expected to be Michael Hoffman. The consummation of the transaction is conditioned upon, among other things: (i) approval for listing of Prologium Class A Ordinary Shares and warrants contemplated to be listed pursuant to the Business Combination Agreement on Nasdaq; (ii) the absence of any governmental order enjoining, restraining, prohibiting or otherwise making illegal the consummation of the Business Combination; (iii) receipt of the required approval by TDAC shareholders; (iv) receipt of the required approval by Prologium shareholders; (v) the effectiveness of the registration statement to be filed by Prologium under the Securities Act of 1933, as amended; (vi) the Second Merger Surviving Company, as successor to TDAC, having at least $5,000,001 of net tangible assets after the consummation of the Business Combination and the closing of any TDAC shareholder redemptions; (vii) completion of the Recapitalization in accordance with the Business Combination Agreement; (viii) lock-up agreement; (ix) registration rights agreement; and (x) Available Cash, as defined in the Business Combination Agreement, being greater than or equal to $250 million. The boards of directors of both ProLogium and TDAC have approved the Transaction, which is expected to close in the second half of 2026.
Venable LLP acted as legal advisor for Translational Development Acquisition Corp. Sullivan & Cromwell LLP acted as legal advisor for Prologium Holdings Inc. BTIG, LLC acted as financial advisor for Translational Development Acquisition Corp. Cohen & Company Capital Markets, LLC acted as financial advisor for Prologium Holdings Inc. LCS & Partners acted as legal advisor for Prologium Holdings Inc. Board Change • May 26
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman of the Board & CEO Michael M. Hoffman is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. 공시 • Dec 24
Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million. Translational Development Acquisition Corp. has completed an IPO in the amount of $150 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 15,000,000
Price\Range: $10
Discount Per Security: $0.55
Transaction Features: Blank Check Blind Pool Company